Streetbeat News

Analyst Ratings

BOH

Keefe, Bruyette & Woods analyst Kelly Motta has maintained an Underperform rating on Bank of Hawaii (NYSE:BOH) and reduced the price target from $57 to $55.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 3:20 pm

INTA

Citigroup analyst Steven Enders has initiated coverage on Intapp (NASDAQ:INTA) with a Buy rating and set a price target of $57 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 3:13 pm

MO

UBS analyst Faham Baig has initiated coverage on Altria Group (NYSE:MO) with a Sell rating and set a price target of $36.1 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 3:08 pm

QTWO

Q2 Holdings (NYSE:QTWO) has received diverse ratings from 8 analysts, with an average 12-month price target of $40.12, reflecting a 19.16% increase from the previous target. Analysts from firms like Goldman Sachs and Morgan Stanley have raised their price targets, indicating a positive outlook for QTWO. The company provides cloud-based virtual banking solutions and has shown a revenue growth rate of 7.06% as of September 30, 2023. However, it faces challenges with a net margin of -14.95% and an ROA of -1.97%, though it has a favorable debt-to-equity ratio of 1.24.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 3:01 pm

WW

Goldman Sachs analyst Jason English has maintained a Buy rating on WW International (NASDAQ:WW) but has reduced the price target from $18 to $12.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 3:01 pm

TXRH

Texas Roadhouse (NASDAQ:TXRH) received mixed analyst ratings with 1 bullish, 3 somewhat bullish, and 3 indifferent. The 12-month price targets have an average of $119.14, with a high of $130.00 and a low of $110.00. Recent analyst actions include adjustments to ratings and price targets by JP Morgan, Wedbush, Piper Sandler, Truist Securities, and Morgan Stanley. Texas Roadhouse's financial health indicators show a solid revenue growth rate of 12.93%, an impressive net margin of 5.69%, an exceptional ROE of 5.83%, and an effective ROA of 2.52%, with a conservative debt-to-equity ratio of 0.69.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 3:01 pm

NBIX

Over the past three months, 13 analysts have provided varied opinions on Neurocrine Biosciences (NASDAQ:NBIX), with recent ratings showing a shift towards a more bullish stance. The average 12-month price target is now $127.54, up from $121.70, with individual targets ranging from $100.00 to $150.00. Analysts have made adjustments to their ratings and price targets, reflecting changes in market conditions and company performance. Neurocrine Biosciences is a pharmaceutical company with late-stage clinical programs for CNS and endocrine-related conditions. Financial indicators show a positive revenue trend, high net margin, and strong ROE and ROA, with a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 3:00 pm

CAKE

Cheesecake Factory (NASDAQ:CAKE) received mixed ratings from 7 analysts, with a shift towards a more bearish stance in the last 30 days. The average 12-month price target is $32.14, down 5.47% from the previous average. Analysts from firms like JP Morgan, Wedbush, Piper Sandler, Barclays, and Stephens & Co. have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Cheesecake Factory's financial indicators show a revenue growth of 5.89%, a high net margin of 2.16%, and an ROE of 5.54%, but a lower ROA of 0.65% and a high debt-to-equity ratio of 5.79.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 3:00 pm

BLMN

Over the past three months, 8 analysts have provided diverse ratings for Bloomin Brands (NASDAQ:BLMN), with recent shifts in sentiment. The average 12-month price target is now $27.25, down from $27.86. Analysts from firms like JP Morgan, Raymond James, Barclays, BMO Capital, Piper Sandler, and UBS have updated their ratings and price targets. Bloomin Brands operates casual dining restaurants and has shown revenue growth and strong ROE and ROA, but faces debt management challenges with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 3:00 pm

CTSH

Cognizant Tech Solns (NASDAQ:CTSH) has received mixed analyst ratings over the past quarter, with 12 analysts offering diverse opinions. The average 12-month price target is $74.83, up from the previous $73.00, with a high estimate of $90.00 and a low of $65.00. Analysts from firms like Barclays, Citigroup, and Jefferies have raised their price targets, while others from BMO Capital, JP Morgan, and Morgan Stanley have lowered theirs. Cognizant's financial performance shows a positive revenue trend, an impressive net margin, and strong ROA, but a below-average ROE and a conservative debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 3:00 pm